Terms: = Breast cancer AND CBLC, CBL-3, 23624, ENSG00000142273, RNF57, Q9ULV8, CBL-SL
4 results:
1. cblc inhibits the proliferation and metastasis of breast cancer cells via ubiquitination and degradation of CTTN.
Li W; Lei T; Song X; Deng C; Lu J; Zhang W; Kuang Z; He Y; Zhou Q; Luo Z; Mo F; Yang H; Hang J; Xiao B; Li L
J Recept Signal Transduct Res; 2022 Dec; 42(6):588-598. PubMed ID: 36043996
[TBL] [Abstract] [Full Text] [Related]
2. Complementary genetic screens identify the E3 ubiquitin ligase cblc, as a modifier of PARP inhibitor sensitivity.
Frankum J; Moudry P; Brough R; Hodny Z; Ashworth A; Bartek J; Lord CJ
Oncotarget; 2015 May; 6(13):10746-58. PubMed ID: 25883215
[TBL] [Abstract] [Full Text] [Related]
3. Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
Kales SC; Nau MM; Merchant AS; Lipkowitz S
PLoS One; 2014; 9(1):e87116. PubMed ID: 24466333
[TBL] [Abstract] [Full Text] [Related]
4. Vav1 fine tunes p53 control of apoptosis versus proliferation in breast cancer.
Sebban S; Farago M; Gashai D; Ilan L; Pikarsky E; Ben-Porath I; Katzav S
PLoS One; 2013; 8(1):e54321. PubMed ID: 23342133
[TBL] [Abstract] [Full Text] [Related]
